Cover Image
市場調查報告書

黃斑部水腫:開發中產品的概要

Macular Edema - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 219738
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
黃斑部水腫:開發中產品的概要 Macular Edema - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 63 Pages
簡介

所謂黃斑部水腫是視網膜黃斑部的浮腫或是體液積存狀態。常見的症狀有視覺中心點模糊、扭曲、或是顏色消失及變化。

本報告涵括全球黃斑部水腫治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品評估等資訊,為您概述為以下內容。

簡介

  • 調查範圍

黃斑部水腫概要

治療藥的開發

  • 開發中產品的概要

黃斑部水腫:企業開發中的治療藥

黃斑部水腫:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

黃斑部水腫:企業開發中的產品

黃斑部水腫的治療藥的開發企業

  • ActiveSite Pharmaceuticals, Inc.
  • Ampio Pharmaceuticals, Inc.
  • Clearside BioMedical, Inc.
  • Clonz Biotech Private Limited
  • Coherus BioSciences, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • Mabion SA
  • Pfizer Inc.
  • Precision Ocular Ltd
  • Promedior, Inc.
  • Taiwan Liposome Company, Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Xbrane Biopharma AB

黃斑部水腫:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

黃斑部水腫:最近的開發平台趨勢

黃斑部水腫:暫停中的計劃

黃斑部水腫:開發中止的產品

黃斑部水腫:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8646IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2016, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 2, 9, 1 and 1 respectively.Macular Edema.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Macular Edema Overview
  • Therapeutics Development
    • Pipeline Products for Macular Edema - Overview
  • Macular Edema - Therapeutics under Development by Companies
  • Macular Edema - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Macular Edema - Products under Development by Companies
  • Macular Edema - Companies Involved in Therapeutics Development
    • ActiveSite Pharmaceuticals, Inc.
    • Ampio Pharmaceuticals, Inc.
    • Chong Kun Dang Pharmaceutical Corp.
    • Clearside BioMedical, Inc.
    • Coherus BioSciences, Inc.
    • Mabion SA
    • Pfizer Inc.
    • Precision Ocular Ltd
    • Promedior, Inc.
    • Taiwan Liposome Company, Ltd.
    • Valeant Pharmaceuticals International, Inc.
    • Xbrane Biopharma AB
  • Macular Edema - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (aflibercept + triamcinolone acetonide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACX-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASPPDC-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLO-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • celecoxib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • danazol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone sodium phosphate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HO-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRM-167 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Macular Edema - Dormant Projects
  • Macular Edema - Discontinued Products
  • Macular Edema - Product Development Milestones
    • Featured News & Press Releases
      • Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
      • Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
      • Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
      • Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration
      • Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Macular Edema, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2016
  • Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Macular Edema - Pipeline by Clearside BioMedical, Inc., H2 2016
  • Macular Edema - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Macular Edema - Pipeline by Mabion SA, H2 2016
  • Macular Edema - Pipeline by Pfizer Inc., H2 2016
  • Macular Edema - Pipeline by Precision Ocular Ltd, H2 2016
  • Macular Edema - Pipeline by Promedior, Inc., H2 2016
  • Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Macular Edema - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Macular Edema - Dormant Projects, H2 2016
  • Macular Edema - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Macular Edema, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top